Form 4: OnKure CFO Sells Shares for Tax Obligations

OnKure Therapeutics' Chief Financial Officer, Jason A. Leverone, sold 301 shares of Class A Common Stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Jason A. Leverone, Chief Financial Officer of OnKure Therapeutics, Inc. (OKUR), reported a sale of company stock.
• The transaction involved 301 shares of Class A Common Stock.
• The shares were sold on March 23, 2026, at a weighted average price of $4.1565 per share.
• The sale was automatic and executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) under the Issuer's 2023 RSU Equity Incentive Plan.
• Following this transaction, Mr. Leverone beneficially owns 16,000 shares, which include certain RSUs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves a sale of shares, it's a non-discretionary transaction to cover tax liabilities from RSU vesting, indicating that equity awards are being realized by management.

Positives

• The sale was not a discretionary decision but an automatic transaction to cover tax liabilities, indicating the vesting of equity awards.
• The vesting of Restricted Stock Units (RSUs) suggests continued employee retention and alignment of interests with shareholders.

Negatives

• No direct negatives are indicated by this routine tax-related sale.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
• This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price.
• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine occurrence across industries. This type of transaction is typically not indicative of a change in management's sentiment towards the company's prospects but rather a standard administrative process related to equity compensation.

Comparison to Industry Standards

• The practice of selling shares to cover tax obligations upon RSU vesting is a standard industry practice for executive compensation plans, aligning with common corporate governance and tax compliance procedures seen in companies like Pfizer, Microsoft, or Apple when their executives' equity awards vest.
• The weighted average sale price of $4.1565, derived from a range of $3.995 to $4.235, reflects typical market execution for such transactions, similar to how institutional brokers handle block trades for tax purposes.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related sale, not a discretionary divestment. It confirms RSU vesting, which is part of executive compensation.
• Employees: Confirms the operation of the company's equity incentive plan, which can be a positive for employee morale regarding compensation.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary sale of shares by the CFO to cover tax obligations arising from RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or management's long-term outlook. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an investor's existing position.

Keywords

OnKure Therapeutics, OKUR, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Jason A. Leverone, Chief Financial Officer, Equity Incentive Plan